Catheter Precision Soars 62.84 on $250M Volume Hits 388th Market Rank After UK Approval Catalyzes HC21 Partnership

On August 18, 2025, Catheter Precision (VTAK) surged 62.84% with a trading volume of $250 million, ranking 388th in market activity. The rally followed regulatory approval for its LockeT suture retention device in the UK, the final step required to launch sales in the region after securing CE Mark approval in May 2025. The company has expanded its partnership with HC21, a UK-based distributor with €180 million annual revenue, to commercialize the product. HC21’s established network across the UK and Ireland positions Catheter to access key healthcare providers efficiently.

LockeT, a Class 1 FDA-registered device, is designed to improve patient outcomes by enabling faster recovery and hospital discharges following cardiac procedures. The product aligns with NHS initiatives to reduce waiting lists by optimizing hospital capacity. Executives emphasized LockeT’s potential to support clinicians in delivering treatments more efficiently, particularly as the NHS recently reported its first reduction in waiting lists in 17 years. The partnership with HC21, which has collaborated with the company on other products, underscores confidence in the device’s market viability.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to present delivered a total profit of $10,720 as of the latest data. Performance remained stable with minor fluctuations influenced by broader market conditions.